Meso Foundation announces 2013 research award grants

5 Feb 2014 by under News, Organizations, Research/Treatment

MARF logo square Meso Foundation announces 2013 research award grantsThe Mesothelioma Applied Research Foundation () this week announced the 2013 recipients of mesothelioma research grant money totaling $500,000. Five projects were selected for funding. Each will receive $100,000. The Foundation has contributed $8.7 million in funding for mesothelioma research since the program began.

Each year, applicants submit their proposed projects for researching treatments, hopefully ultimately leading to a cure, for mesothelioma. Mesothelioma is a deadly form of cancer caused by exposure. It most commonly affects the lining of the lungs (pleural mesothelioma) or the abdomen (peritoneal mesothelioma) but may also rarely affect the lining of the heart (pericardial mesothelioma). There is currently no known cure for mesothelioma. Researchers estimate at least 3,000 people are diagnosed with mesothelioma each year.

The Meso Foundation opened the grant application process in April 2013, and received a total of 49 applications. These were peer-reviewed by the Foundation’s Science Advisory Board, made up of 18 mesothelioma experts from around the world. The peer review process is modeled on that used by the National Cancer Institute.

“All five of these projects are remarkable and hold much promise in their ability to add to our currently limited arsenal for treating mesothelioma,” Mary Hesdorffer, Nurse Practitioner, Executive Director for the Meso Foundation, said in a news release. “I am very proud of the life-saving work our mesothelioma researchers are doing.”

The grant recipients include Marc De Perrot, MD, of the University Health Network for his project “Optimizing the radiation approach to mesothelioma with immunotherapy”; Christian Ottensmeier of the University of Southampton for his project “Evaluating the effect of immunity on outcomes of patients with mesothelioma”; Tao Dao, MD, PhD, of the Memorial Sloan-Kettering Cancer Center for his project “Specific immunotherapy for mesothelioma by use of bi-specific TCR-like antibody“; Usha Pendurthi, PhD, of the University of Texas Health Science Center at Tyler for her project “Endothelial Cell Protein C Receptor Attenuates Mesothelioma Progression”; and Elisa Giovannetti, MD, PhD, of the VU University Medical Center for her project “Novel lactate dehydrogenase inhibitors for the treatment of mesothelioma.”

The Meso Foundation (formerly MARF) is the only non-profit organization dedicated to ending mesothelioma and the suffering caused by it, by funding research, providing education and support for patients and their families, and by advocating for federal funding of mesothelioma research.

Source: Meso Foundation

Comments are closed.